Open Access

High levels of cellular proliferation predict pseudoprogression in glioblastoma patients

  • Authors:
    • Henri-Benjamin Pouleau
    • Niloufar Sadeghi
    • Danielle Balériaux
    • Christian Mélot
    • Olivier De Witte
    • Florence Lefranc
  • View Affiliations

  • Published online on: November 11, 2011     https://doi.org/10.3892/ijo.2011.1260
  • Pages: 923-928
  • Copyright: © Pouleau et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Radiochemotherapy (RT) with concomitant followed by monthly temozolomide (TMZ) chemotherapy is the gold standard for the treatment of glioblastoma (GBM) patients. GBM patients can experience transient radiological deterioration after concurrent RT/TMZ that stabilizes or even resolves after additional cycles of adjuvant TMZ, a phenomenon defined as radiological pseudoprogression. The aim of this retrospective study was to identify a reliable marker associated with pseudoprogression processes. Patients with histologically proven newly diagnosed GBM were identified from a retrospective database between 2005 and 2009. Predictive factors for pseudoprogression were analyzed from clinical, radiological and biological data. Of the 130 analyzed patients, 63 underwent RT/TMZ treatment followed by cycles of TMZ and were evaluated for radiological responses every two months by magnetic resonance imaging. Early progression was confirmed in 52% (33/63) of the patients, and, within this group, 21% (7/33) displayed evidence of pseudo-progression. The predictive factors were evidenced in terms of clinical or radiological findings. In GBM patients, the level of cellular proliferation (Ki67 indices) emerged as a statistically significant prognostic marker for distinguishing pseudoprogression from actual progression. Our observation, suggesting that GBM associated with a high level of cellular proliferation may differentiate tumor progression from pseudoprogression, warrants further investigation in a large multi-center prospective study.
View Figures
View References

Related Articles

Journal Cover

April 2012
Volume 40 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Pouleau H, Sadeghi N, Balériaux D, Mélot C, De Witte O and Lefranc F: High levels of cellular proliferation predict pseudoprogression in glioblastoma patients. Int J Oncol 40: 923-928, 2012
APA
Pouleau, H., Sadeghi, N., Balériaux, D., Mélot, C., De Witte, O., & Lefranc, F. (2012). High levels of cellular proliferation predict pseudoprogression in glioblastoma patients. International Journal of Oncology, 40, 923-928. https://doi.org/10.3892/ijo.2011.1260
MLA
Pouleau, H., Sadeghi, N., Balériaux, D., Mélot, C., De Witte, O., Lefranc, F."High levels of cellular proliferation predict pseudoprogression in glioblastoma patients". International Journal of Oncology 40.4 (2012): 923-928.
Chicago
Pouleau, H., Sadeghi, N., Balériaux, D., Mélot, C., De Witte, O., Lefranc, F."High levels of cellular proliferation predict pseudoprogression in glioblastoma patients". International Journal of Oncology 40, no. 4 (2012): 923-928. https://doi.org/10.3892/ijo.2011.1260